PI3K status has been identified as a key factor for response to anti‐EGFR treatment in metastatic colorectal cancer; however, we suggest that PrPC/EGFR may have utility in p38MAPK driven and BRAF colorectal cancers (Lièvre et al., 2017). This evidence concerns the gene BRAF and metastatic colorectal cancer.